Cargando…
Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient wit...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063779/ https://www.ncbi.nlm.nih.gov/pubmed/37006273 http://dx.doi.org/10.3389/fimmu.2023.1127868 |
_version_ | 1785017766499057664 |
---|---|
author | Zhang, Qi Zhu, Xiaojian Liu, Bo Zhang, Yicheng Xiao, Yi |
author_facet | Zhang, Qi Zhu, Xiaojian Liu, Bo Zhang, Yicheng Xiao, Yi |
author_sort | Zhang, Qi |
collection | PubMed |
description | Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient with r/r BL who failed to achieve complete remission (CR) and progressed rapidly after multiple protocol chemotherapy. The patient achieved CR with CAR19 and CAR22 T-cell cocktail therapy and obtained long-term disease-free survival after autologous hematopoietic stem cells (ASCT) and subsequential CAR19 and CAR22 T-cell cocktail therapy. The clinical evolution and genetic features of this case may provide some guidance for CAR-T therapy in overcoming relapses associated with TP53 gene mutations. |
format | Online Article Text |
id | pubmed-10063779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100637792023-04-01 Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations Zhang, Qi Zhu, Xiaojian Liu, Bo Zhang, Yicheng Xiao, Yi Front Immunol Immunology Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient with r/r BL who failed to achieve complete remission (CR) and progressed rapidly after multiple protocol chemotherapy. The patient achieved CR with CAR19 and CAR22 T-cell cocktail therapy and obtained long-term disease-free survival after autologous hematopoietic stem cells (ASCT) and subsequential CAR19 and CAR22 T-cell cocktail therapy. The clinical evolution and genetic features of this case may provide some guidance for CAR-T therapy in overcoming relapses associated with TP53 gene mutations. Frontiers Media S.A. 2023-03-17 /pmc/articles/PMC10063779/ /pubmed/37006273 http://dx.doi.org/10.3389/fimmu.2023.1127868 Text en Copyright © 2023 Zhang, Zhu, Liu, Zhang and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhang, Qi Zhu, Xiaojian Liu, Bo Zhang, Yicheng Xiao, Yi Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
title | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
title_full | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
title_fullStr | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
title_full_unstemmed | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
title_short | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
title_sort | case report: sandwich therapy of car-t combined with asct: sequential car-t cell therapy with asct after remission with car-t therapy caused long-term survival in a patient with relapsed/refractory burkitt’s lymphoma with tp53 mutations |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063779/ https://www.ncbi.nlm.nih.gov/pubmed/37006273 http://dx.doi.org/10.3389/fimmu.2023.1127868 |
work_keys_str_mv | AT zhangqi casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations AT zhuxiaojian casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations AT liubo casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations AT zhangyicheng casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations AT xiaoyi casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations |